Temozolomide Access in Ontario
CNETS is pleased to share the news that the oral chemotherapy drug, temozolomide, often used in combination with capecitabine, known as the CAPTEM regimen, is now more accessible to [...]
Lutathera Funded in Saskatchewan
As of June 1, 2021, Lutathera is now available in Saskatchewan. The reimbursement criteria is for patients with unresectable, well-differentiated midgut* neuroendocrine tumors (NET) in patients who have experienced [...]
How a better image can save a life
The Globe and Mail: How a better image can save a life Sharon Needham, with oncologist Dr. Daniel Rayson, and radiologist Dr. Steven Burrell, at [...]
COVID-19 VACCINE & NEUROENDOCRINE CANCER PATIENTS
Disclaimer: CNETS is a patient organization, and we are unable to provide medical advice. Any information or guidance contained herein should not replace personalized medical advice. Our objective is [...]
LUTATHERA Funded In British Columbia
CNETS is happy to announce that BC Cancer will now reimburse LUTATHERA for the approved indication. The BC Cancer Benefit Drug List, Published March 2021, Tumour Site: Gastrointestinal Peptide [...]
INSPIRATIONAL NET CANCER PATIENT STORY
INSPIRATIONAL NEUROENDOCRINE CANCER PATIENT STORY Long-time CNETS fundraisers Bryde Fresque and Natalie Mezey, share a message of hope! As outlined in this Ottawa Hospital Foundation report, Bryde Fresque [...]
ESMO Guidelines: Lung & Thymic Carcinoids
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Published January 19, 2021 Highlights This updated ESMO Clinical Practice Guideline [...]
European Journal of Cancer Article
Article: Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era February 2021 - European Journal of Cancer, Review [...]
INCA NETInfo
INCA GLOBAL NET PATIENT INFO PACK NEW FOR 2020! - NETInfo INCA launches a range of factsheets on NETs that are free to download. These factsheets provide [...]
LUTATHERA® Funded in Ontario
Radiopharmaceutical cancer treatment Lutathera® now available to Ontario patients with midgut neuroendocrine tumours (NETs). The Ontario funding criteria covers the treatment of adult patients with somatostatin receptor-positive (SSR+) midgut NETs [...]